Personalized shopping, stock trading, and online portals - all have become hallmarks to our new information driven culture that has become increasingly focused on the individual. Looking beyond these innovations, the focus on addressing the individual needs of patients, or more commonly known as personalized medicine, has become a focal point within the debates of healthcare reform. But is personalized medicine really something that we can enact within the confines of the current IT infrastructure and patient educational services?
Tags: Personalized Medicine, Product Strategy, Investor Strategy, Global Strategy, Patient Strategy
The talk of the town since the conclusion of this historic election has been understandably focused on on how to fix the economy, pull out of Iraq over the next 16 months, and pursue clean energy alternatives. The magnitude of tasks that President-elect Obama has to contend with are staggering and each of them demand immediate action and long-term vision. However, through the fog of campaign rhetoric and economic meltdown in the US and in Europe, very little has been said about how the United States can take a real leadership position with helping to eradicate global disease through the commercialization of affordable life- saving therapeutics and vaccines for developing countries.
Tags: Product Strategy, Investor Strategy, Clinical Trial Strategy, Non-Profits
Our clients know that the litany of negative headlines from the financial sector in the past month has not escaped the eyes and minds of marketing departments budget crunchers throughout the life sciences. In response to the economic uncertainty, many biotech and pharma companies are cutting non-core spending to maintain internal stability. Reduced budgets present the proverbial challenge that "tools are needed to build a ship." Yet marketers are charged with delivering the corporate or product message out, building sales and partnerships, and developing brand awareness. In this catch-22, how can the industry best stretch its marketing dollars?
Tags: SEM, RSS, Online Marketing, Viral Marketing, Product Strategy, Investor Strategy, Clinical Trial Strategy
In a time when most conversations I have with clients revolve around how the global economical state of affairs is going to affect their marketing budgets for 2009, my response has been clear and unchanged - it's time to smarten up. Investors are more critical than ever on fiscal performance, managers have to keep close control of their spending and report on results, all of which is compounded by the FDA who is starting to crack down on claims made within DTC advertising. We have to stay focused, and more than ever, find ways to be efficient and strategic with our initiatives.
Tags: Online Marketing, Viral Marketing, DTC Advertising, Product Strategy, Global Strategy, Investor Strategy
If you are raising money right now you are probably experiencing a "wait and see" moment across the board from people making $50 donations to people making much larger long-term investments. The current market uncertainty can really impact your business and the decisions you make in response to those external forces are critical.